Actively Recruiting
Phase II Study to Assess the Safety and Effectiveness of VC005 Tablets for Adults with Non-segmental Vitiligo
Led by Jiangsu vcare pharmaceutical technology co., LTD · Updated on 2026-01-02
120
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This clinical trial is a phase II, multicenter, randomized, double-blind, controlled study evaluating the efficacy and safety of VC005 tablets in people with non-segmental vitiligo. The trial is sponsored by Jiangsu vcare pharmaceutical technology co., LTD and aims to assess how well VC005 works for this skin condition. Participants will be randomly assigned to one of three groups low-dose VC005 tablets, high-dose VC005 tablets, or a placebo group. All groups will receive their assigned treatment repeatedly for 52 weeks. The study includes a placebo control to compare the effects of VC005 tablets at different doses. During the study, participants facial vitiligo area will be measured to track changes from baseline up to week 24. The main outcome is the percentage change in the facial vitiligo area score index F-VASI. The trial will monitor participants for a total duration of up to 52 weeks, with ongoing assessments to evaluate safety and treatment effects.
CONDITIONS
Brief Title
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Research Team
X
xiaojuan lai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here